We studied the defect responsible for Glanzmann thrombasthenia in a patient whose platelets expressed < 5% of the normal amount of GPIIb-IIIa. Genetic and biochemical evidence indicated that the patient's GPIIIa genes were normal. However, DNA analysis revealed the patient homozygous for a G818 A substitution in her GPIIb genes, resulting in a Gly273 -> Asp substitution adjacent to the first GPIIb calcium-binding domain. To determine how this mutation impaired GPIIb-IIIa expression, recombinant GPIIb containing the mutation was coexpressed with GPIIIa in COS-1 cells. The GPIIb mutant formed stable GPIIb-IIIa heterodimers that were not immunoprecipitated by either of two heterodimer-specific monoclonal antibodies, indicating that the mutation disrupted the epitopes for these antibodies. Moreover, the GPIIb in the heterodimers was not cleaved into heavy and light chains, indicating that the heterodimers were not transported from the endoplasmic reticulum to the Golgi complex where GPIIb cleavage occurs, nor were the mutant heterodimers expressed on the cell surface. These studies demonstrate that a Gly273 --Asp mutation in GPIIb does not prevent the assembly of GPIIb-IIIa heterodimers, but alters the conformation of these heterodimers sufficiently to impair their intracellular transport. The impaired GPIIb-IIIa transport is responsible for the thrombasthenia in this patient. (J. Clin. Invest. 1994. 93:172-179.) Key words: bleeding disorder -platelet aggregation * glycoprotein lIb-IIla. in vitro mutagenesis * protein conformation
Introduction
The platelet membrane glycoproteins lIb and Ila form heterodimers that contain binding sites for fibrinogen, fibronectin, von Willebrand factor, and vitronectin after platelet activation ( 1 ). Because a sufficient number of functional GPIIb-IIIa heterodimers on the platelet surface is required for normal platelet aggregation, deficiency or dysfunction of GPIIb-IIIa results in the autosomal recessive bleeding disorder Glanzmann thrombasthenia (2) . By electron microscopy, GPIIb-IIIa in deter-gent solution consists of an 8 X 12-nm globular head with two 18-nm flexible tails extending from one side (3) . The globular head of GPIIb-IIIa contains the amino termini of GPIIb and GPIIIa and the ligand binding domain of the heterodimer, while each tail contains the transmembrane domain and carboxyl terminus of one subunit. The GPIIb-IIIa heterodimer is calcium dependent (1) , and in the presence of calcium chelators GPIIb-IIIa dissociates into two comma-shaped structures, each containing a single tail and a portion of the nodular head (3) . The primary sequences of GPIIb and GPIIIa have been deduced from analyses of cDNA clones, revealing that GPIIbIIa is a member of the integrin family of adhesion receptors (4) (5) (6) (7) . The GPIIb sequence also contains four repeated domains with the consensus sequence Asp-X-Asp-X-Asp-Gly-X-X-Asp-X-X-Val, a sequence resembling calcium-binding domains in many proteins (4, 8) . Whether calcium binding to these domains is involved in GPIIb-IIIa heterodimer assembly or other aspects of GPIIb-IIIa function remains to be determined.
The genes for GPIIb and GPIIIa reside in proximity on the long arm of human chromosome 17 at q21 --22 (9) . After gene transcription, nascent GPIIb and GPIIIa are assembled into heterodimers in the rough endoplasmic reticulum (ER) ' and are transported to the Golgi complex where GPIIb undergoes cleavage into disulfide-linked heavy and light chains (10) (11) (12) . Studies in vitro indicate that in the absence ofheterodimer assembly GPIIb and GPIIIa are retained in the ER and eventually are degraded ( 13 ). Nevertheless, heterodimer assembly by itself does not ensure normal GPIIb-IIIa expression since mutations in GPIIb or GPIIIa that alter the quaternary structure of the heterodimer result in retention and degradation of the heterodimers as well ( 13 ) . In this paper, we report studies of a patient with Glanzmann thrombasthenia whose platelets contained a markedly decreased number of GPIIb-IIIa heterodimers on their surface. We found that the patient's thrombasthenia resulted from a point mutation in the gene for GPIIb. Despite this minimal change, the mutation altered the conformation of the GPIIb-IIIa heterodimer and, as a consequence, impaired the intracellular transport of the mutant heterodimers from the ER to the cell surface.
Methods
Clinical history. The propositus is an Ashkenazi Jewish female child, the product of a consanguineous marriage, who presented at 2 d of age with subdural bleeding and extensive ecchymoses. Although the patient had a normal platelet count, she had a prolonged cutaneous bleed-ing time. Subsequent studies revealed absent ex vivo platelet aggregation in response to ADP (2-10 AM), collagen (0.047-0.19 mg/ml), and epinephrine (2.5-10 MM), but normal platelet agglutination in response to ristocetin. The patient responded well to a platelet transfusion and has had no long-term neurological sequelae. However, the patient has continued to experience extensive ecchymoses and occasional epistaxis, but has not required further hospitalization or platelet transfusion.
Blood samples for the studies described below were obtained from the patient, her parents and other family members, and normal volunteers after informed consent. These studies were approved by the Committee for Protection ofHuman Subjects Institutional Review Board of the Children's Hospital of Philadelphia.
Flow cytometry. Flow cytometry using a panel ofmAbs conjugated with FITC was performed as previously described ( 14) . Monoclonal antibodies used for these studies were A2A9, an antibody that only interacts with intact GPIIb-IIIa heterodimers and recognizes an epitope located in the globular head of GPIIb-IIIa (3, 15) ; Bl B5, an antibody that recognizes an epitope located near the carboxyl terminus of the GPIIb heavy chain (3, 4) ; SSA6, an antibody that recognizes an epitope located within a 66,000-mol wt chymotrypsin-derived fragment of GPIIIa (3, 16); PAC-1, an antibody specific for the activated conformation of GPIIb-IIIa (17); and API, an antibody specific for platelet glycoprotein lb ( 18) . In the case ofPAC-1, platelets were stimulated with 0.2 MM phorbol myristate acetate for 5 min at 250C before adding the antibody.
Immunoblot analysis ofplatelet proteins. Immunoblotting ofplatelet proteins was performed as described previously (13) . Briefly, washed platelets were dissolved in 0.01 M Tris-HCl buffer, pH 6.8, containing 3% SDS by heating at 100IC, and 100 Mg of soluble platelet protein was electrophoresed in 0.1% SDS-7.5% polyacrylamide gels under reducing conditions. Then the separated proteins were transferred to nitrocellulose paper (0.45 Mm; Schleicher & Schuell, Inc., Keene, NH), and the paper was incubated with polyclonal anti-GPIIb or GPIIIa antisera at a concentration of 50 g/ ml. Sites of antibody binding were detected with 125I-labeled staphylococcal Protein A (Boehringer Mannheim Corp., Indianapolis, IN). The labeled blots were dried and exposed to Kodak X-Omat AR film at -70'C.
Quantitation ofplatelet av-GPIIIa. The number ofav-GPIIIa complexes per platelet was quantitated as previously described (19) . Briefly, blood was obtained from the patient and three controls in Philadelphia, anticoagulated with 0.18 vol acid-citrate-dextran formula A, coded, and sent directly to the State University of New York at Stony Brook. Blood from an additional control was drawn in Stony Brook. Then platelet-rich plasma was either adjusted to a platelet count of 3 X I05/ Al using platelet-poor plasma for binding studies using the antiGPIba mAb 6D1 (20) Identification ofthe mutation responsiblefor thrombasthenia in the propositus. Genomic DNA and total platelet RNA were isolated from the propositus, family members, and controls as previously described (22) . Platelet RNA was converted to cDNA using AMV reverse transcriptase (Gibco Laboratories, Grand Island, NY) before analysis. PCR amplification and DNA sequence analysis of the GPIIb coding sequence were accomplished using oligonucleotides based on known cDNA and genomic sequences (4, 23) . Oligonucleotides were synthesized using a DNA synthesizer (380B; Applied Biosystems, Inc., Foster City, CA) and were used without further purification. PCR amplification was performed using a thermal cycler (BIOS Labs., New Haven, CT) for 30 cycles under the following conditions: denaturation, 940C for 30 s; annealing, 60C for 30 s; and extension, 720C for 30 s. The reaction volume was 100 Ml and consisted of 10 mM Tris-HCl buffer, pH 8.3, containing 10 pmol of each primer, 2.5 mM MgCl2, 50 mM KCl, 0.0 1% gelatin, 0.2 mM dNTP, and 1 U Taq I polymerase (PerkinElmer Corp., Norwalk, CT). The PCR products were directly sequenced in both directions using a Taq polymerase chain termination approach and [132P_]ATP end-labeled oligonucleotides (24) .
Allele-specific analysis by PCR was used to determine whether the propositus was homozygous for GPIIb orGPIIIa polymorphisms (25) . PCR amplification of 200 ng of genomic DNA was performed for 30 cycles in a thermal cycler (Perkin-Elmer Corp.) using the following conditions: denaturation at 95°C for 1 min, annealing at 66°C for 2 min, and extension at 72°C for 2 min. 20-Mul aliquots of each reaction were then electrophoresed in a 1% agarose gel in the presence of ethidium bromide for 60 min at 50 mA.
Heterologous expression of recombinant GPIIb-IIIa. The effect of mutations on GPIIb-IIIa expression was examined by introducing the mutation into the sequences ofwild-type cDNAs by site-directed mutagenesis as described previously (12) . After confirmation of the site-directed mutation by DNA sequencing, the mutant cDNA was shuttled into the expression vector pMT2ADA (26) and was introduced into COS-l cells using the DEAE-dextran method as described previously (12) . To avoid flask-to-flask variation in transfection efficiency, cells were harvested at 24 h, pooled, and replated, and incubation was continued for an additional 24 h. 48 h after transfection, the COS-l cells were labeled with [35S]methionine (Dupont NEN Research Products, Boston, MA) at 200 ,Ci/ml for 60 min before harvesting. For pulsechase studies, media containing labeled methionine were removed and replaced with media containing unlabeled methionine for various periods of time before the cells were harvested.
At 48 h, labeled cells were disrupted with a plastic cell scraper (Fisher Scientific Co., Pittsburgh, PA) and were extracted overnight at 4°C with 0.02 M Tris-HCl buffer, pH 7.8, containing 1% Triton X-100 (Sigma Immunochemicals, St. Louis, MO). Then the extracts were cleared by incubation with 4 Ml of nonimmune mouse serum for 15 min at 4°C, followed by an incubation with 100 Ml of a 10% suspension of fixed Staphylococci (Pansorbin; Calbiochem Corp., La Jolla, CA) for 30 min at 4°C. Recombinant GPIIb, GPIIIa, or GPIIb-IIIa were immunoprecipitated by adding 25 Mg of a murine mAb to 500-,Ml aliquots of the cleared cell extracts. The monoclonal antibodies used for these immunoprecipitations were B1B5, SSA6, and A2A9 (described above), and a second heterodimer-specific antibody 1OE5 (27) . After incubation for 1 h at 4°C, immune complexes were collected using Protein A agarose (GIBCO BRL, Gaithersburg, MD), eluted at 100°C with 0.01 M Tris-HCl buffer, pH 6.8, containing 3% SDS, and electrophoresed on 0.1% SDS-7.5% polyacrylamide slab gels. Gels were fixed with 10% acetic acid, treated with Autofluor (National Diagnostics Inc., Manville, NJ), dried, and exposed to Kodak X-Omat AR film at -70°C. Apparent molecular weights of the immunoprecipitated proteins were determined from the mobilities of prestained protein molecular weight markers obtained from Bio-Rad Laboratories (Richmond, CA).
Recombinant GPIIb-IIIa heterodimers were detected on the surface of cotransfected COS-1 cells after labeling the cell surface with 1251 using lactoperoxidase/H202 (13) . Surface-labeled cells were extracted with 1% Triton X-100, and proteins were immunoprecipitated from the extracts using a polyclonal anti-GPIIb antisera that interacts with determinants on both the heavy and light chains of GPIIb.
Results
Quantitation of GPIIb-IIIa in propositus platelets. The complete absence of agonist-stimulated platelet aggregation sug-gested that our patient suffered from Glanzmann thrombasthenia (2). To confirm this diagnosis, we measured GPIIb-IIIa expression on the surface of the patient's platelets using flow cytometry and a panel ofGPIIb-IIIa-specific monoclonal antibodies. As seen in Fig. 1 , < 5% of the normal amount of GPIIb-IIIa was detected on the surface ofthe patient's platelets after reacting the platelets with the GPIIb-specific mAb B lB5 or the GPIIIa-specific mAb SSA6. Somewhat less GPIIb-IIIa (< 2%) was measured after reacting resting platelets with the heterodimer-specific mAb A2A9 or after activating the platelets with phorbol myristate acetate and reacting with the activation-dependent anti-GPIIb-IIIa mAb PAC-1. These values are near the limits of sensitivity ofthe flow cytometer and indicate that little, if any, GPIIb-IIIa was present on the surface of the patient's platelets. On the other hand, the platelets bound a normal amount of the anti-GPIb mAb AP-1, verifying that the abnormality in the platelets was limited to the GPIIb-IIIa complex.
Despite the marked reduction in GPIIb-IIIa antigen on the surface of the patient's platelets, it was possible that sufficient GPIIb-IIIa remained to be detected by immunoblotting. To test this possibility, equal quantities of protein from patient and control platelets were subjected to SDS-PAGE under reducing conditions and were immunoblotted using either polyclonal GPIIb or GPIIIa antisera. The results of these experiments are shown in Fig. 2 . Immunoblotting of protein from control platelets revealed prominent bands corresponding to GPIIIa and to the GPIIb heavy chain (GPIIba) and GPIIb light chain (GPIIbfl). In contrast, immunoblotting of protein from patient platelets revealed a faint GPIIIa band when anti-GPIIIa antisera was used and a faint band corresponding to a protein with a molecular weight of 140,000 when anti-GPIIb antisera was used. Thus, these immunoblots indicate that a small amount of normal size GPIIIa remained in the patient's platelets. The blots also suggest that the residual GPIIb in the patient's platelets consisted primarily of the uncleaved 140,000-mol wt GPIIb precursor pro-GPIIb (4, 13). Several additional bands were also present on the control and patient immuno- blots when the GPIIb antisera was used and likely resulted from the presence of antibodies with other specificities in the antisera. Identification ofthe mutation responsiblefor thrombasthenia in the propositus. Because it was not possible to determine from the immunoblots whether a mutation in GPIIb or in GPIIIa was responsible for the patient's thrombasthenia, we took advantage ofthe observation that the number ofvitronectin receptors (av-GPIIIa) may be increased in the platelets of thrombasthenic patients with GPIIb abnormalities and decreased in the platelets ofthrombasthenic patients with GPIIIa abnormalities (19, 28) . To determine the number of avGPIIIa heterodimers expressed on the patient's platelets, we measured the binding of the anti-vitronectin receptor mAb LM609 to patient and control platelets at a series of subsaturating concentrations. The patient's platelets bound 173-227% as much antibody as the controls (Table I) . From these data, we concluded that it is likely that the genetic abnormality responsible for the patient's thrombasthenia was present in her genes for GPIIb. In support of this conclusion, we also observed that the patient was heterozygous for a polymorphism in the GPIIIa intron xi sequence 5'-TTCCC(C/T)GG-3' that is located 85 bp upstream from exon xii (data not shown). Accordingly, because the patient is the offspring of a consanguineous marriage, we would have anticipated her to be homozygous, rather than heterozygous, for this polymorphism if her genetic abnormality had resided in her GPIIIa genes.
Because our preliminary data suggested that a GPIIb mutation was responsible for the patient's thrombasthenia, the nucleotide sequence for approximately two thirds of the coding region of her GPIIb genes was determined using PCR-amplified genomic and platelet-derived cDNA. Using the sense primer 5'-GTGGTCACTCAGGCCGGAGAG-3' and the antisense primer 5 '-CCATATACAGTGGAGCGCCCACC-3', corresponding to nucleotides 613-633 and 1,068-1,046 of the published GPIIb cDNA sequence, respectively, we detected a base substitution of G --A at position 818 of the GPIIb reading frame (4) (Fig. 3 A) . This substitution results in a Gly273 --Asp amino acid substitution within the first of the four repeats in the GPIIb protein that contain its putative calcium-binding domains (4) . To establish that the patient was homozygous for this DNA substitution, allele-specific PCR analysis was performed using genomic DNA, an antisense oligonucleotide primer 5'-CCTGAGAACTGGGATAAGG-3' derived from intron 9 of the GPIIb gene (24) , and either of two sense oligonucleotide primers, 5'-GGTACTCGGTGGCCGTGGG-3' or 5'-GGT-ACTCGGTGGCCGTGGA-3', corresponding to nucleotides 800-818 of the wild-type or mutant GPIIb coding sequence, respectively (4). As seen in Fig. 3 B, a DNA fragment of the expected size was generated by PCR using wild-type genomic DNA and the wild-type, but not the mutant, sense primer. Conversely, an identically sized DNA fragment was generated using patient DNA and the mutant, but not the wild-type, sense primer. However, using genomic DNA obtained from the patient's mother, DNA fragments of identical size were generated using either the wild-type or the mutant primer, confirming with the mother's status as an obligate heterozygote for the mutation. Identical results were obtained using paternal DNA (data not shown). To further examine the pattern of inheritance ofthe GPIIb mutation, allele-specific PCR analysis and measurements of platelet-surface GPIIb-IIIa using flow cytometry were performed using DNA and platelets obtained from other members ofthe patient's family (Fig. 4) . There was complete concordance between the PCR analysis and the GPIIb-IIIa measurements, such that ;n-50% levels of GPIIbIlIa were present on the platelets of obligate carriers and _ 100% levels were present on the platelets of nonaffected family members. These data confirm the autosomal recessive pattern of inheritance of the G818 --A base substitution and verify that the patient is homozygous at this position.
Expression of GPIIb containing Gly273 -a Asp in COS-J cells. To verify that the glycine -> aspartic acid substitution resulting from the G8 18 -* A mutation actually interferes with GPIIb-IIIa expression, we introduced the mutation into the sequence ofa wild-type GPIIb cDNA by site-directed mutagen- RNA by PCR. The analysis revealed a single G --A base substitution at nucleotide 818 ofthe GPIIb reading frame. This substitution converts the codon for amino acid residue 273 from GGC encoding glycine to GAC encoding aspartic acid. (B) Allele-specific analysis of the GPIIb genes. Genomic DNA, isolated from a normal control, the patient's mother, and the patient was amplified by PCR using a common 3' oligonucleotide derived from intron 9 ofthe GPIIb gene and either of two 5' oligonucleotides derived from exon 8, one ending in the normal G or one ending in the A mutation. The PCR products were then examined by agarose gel electrophoresis and ethidium bromide staining. A (Fig. 5 B) . An Figure 4 . Inheritance of the thrombasthenic mutation in the patient's family. Allele-specific analysis of genomic DNA obtained from members of the patient's family was performed as described in Fig.  3 . The results of the analysis are indicated by the shading of the symbols: o, unaffected; o, heterozygote; and ., homozygote. The GPIIbIIIa content of each family member's platelets was also determined by flow cytometry using the anti-GPIIb mAb B I B5 as described in Fig.  1 . The GPIIb-IIIa content was then compared with that of a normal control studied concurrently and is shown as a percentage of the control below each symbol.
was seen when the immunoprecipitations were performed using another heterodimer-specific mAb, lOE5 (data not shown). There are three possible explanations for this result:
(a) the GPIIb mutant may be unable to associate with GPIIIa to form heterodimers; (b) heterodimers do form, but are unstable and do not persist for a sufficient time to be recognized by A2A9 or lOE5; and (c) the GPIIb mutation alters the conformation of GPIIb-IIIa and, in the process, disrupts the epitopes for these complex-specific antibodies.
To test whether the GPIIb mutant is unable to associate with GPIIIa to form heterodimers, we repeated the cotransfections, but performed the immunoprecipitations using the antiGPIIIa mAb SSA6 (Fig. 5 C) GPIIb using GPIIb-specific polyclonal antisera. Pro-lIb is the singlechain GPIIb precursor; Ilba is the GPIIb heavy chain that appears after GPIIb cleavage in the Golgi complex.
lates the consequences of the naturally occurring GPIIb mutation.
Because wild-type GPIIb-IIIa, but not GPIIb or GPIIIa alone, is transported out of the ER ( 10, 11 ) , it is possible that heterodimers containing the GPIIb mutant are unstable and dissociate before they can undergo transport. To test this possibility, we performed a pulse-chase analysis of cells coexpressing wild-type GPIIIa and either wild-type or mutant GPIIb. Transfected cells were pulse-labeled with [35S] methionine for 1 h and were chased with media containing unlabeled methionine for various periods of time before GPIIb-IIIa heterodimers were immunoprecipitated using SSA6. As seen in Fig.  6 , there was essentially no difference in the stability of GPIIbII1a heterodimers containing either the wild-type or mutant GPIIb over the course of the 8-h chase. However, as expected from results illustrated in Fig. 5 , a fraction ofthe wild-type, but not the mutant, GPIIb in the heterodimers was cleaved into heavy and light chains. Thus, these experiments exclude heterodimer instability as an explanation for the inability of heterodimers containing the GPIIb mutant to be transported out of the ER. Consequently, they suggest that it is the altered GPIIbII1a conformation, induced by the GPIIb mutation, that inhibits the egress of GPIIb-IIIa from the ER to the Golgi complex.
Discussion
Glanzmann thrombasthenia results from quantitative and/or qualitative abnormalities in the platelet-membrane GPIIb-IIIa GPIIb-IIIa heterodimers were immunoprecipitated using the GPIIIa-specific mAb SSA6.
heterodimer that preclude platelet aggregation and prevent normal primary hemostasis (2 G8 18 A base substitution in the patient's immediate family using allele-specific PCR. These studies established that the patient was homozygous at this position and increased our confidence that G818 -. A substitution was indeed pathogenic.
To confirm our presumption that the substitution of Gly273 with Asp actually impairs GPIIb-IIIa expression and therefore was responsible for the patient's thrombasthenia, we introduced the G --A base substitution into the wild-type GPIIb sequence by site-directed mutagenesis and expressed the GPIIb mutant, with and without wild-type GPIIIa, in COS-l cells. Although the mutation did not appear to impair the biosynthesis of recombinant GPIIb, we were unable to immunoprecipitate recombinant heterodimers containing the GPIIb mutant with A2A9, a heterodimer-specific mAb that readily immunoprecipitates wild-type GPIIb-IIIa complexes ( 13) . Because neither GPIIb nor GPIIIa appear on the platelet surface in the absence of heterodimer formation, this result suggested that the mutation might produce thrombasthenia by interfering with the process of heterodimer assembly.
A characteristic feature of integrin a subunits like GPIIb is the presence of three or four homologous repeats that are similar to domains in calcium-binding proteins such as calmodulin and troponin C and whose negatively charged amino acids are thought to be responsible for calcium binding ( 1) . Recently, a GPIIb fragment containing its four calcium-binding domains was expressed as a bacterial fusion protein and was shown to contain two classes of calcium-binding sites with dissociation constants of 30 and 120 ,M (29). Nevertheless, the role these domains play in GPIIb-IIIa structure and function is not known. Gly273 in GPIIb is located at the carboxyl-terminal end of a stretch of uncharged residues that has been highly conserved among integrin a subunits and is immediately adjacent to the first calcium-binding domain (7) . Because the GPIIb-IIIa heterodimer is calcium dependent (1) and a chymotrypsin-derived amino-terminal fragment of GPIIb-IIIa containing the calcium-binding domains dissociates in the presence ofcalcium chelators (30), we postulated that a Gly273 --Asp mutation might interfere with heterodimer assembly by disrupting the function of the first calcium-binding domain. However, when immunoprecipitations were performed with an antibody directed against an epitope present in the carboxylterminal tail of GPIIIa (3), we found that the GPIIb mutant readily formed stable heterodimers with GPIIIa. This result suggests that the first calcium-binding domain, by itself, is not responsible for heterodimer formation. Moreover, in preliminary experiments, we found that removal of each of the four calcium-binding domains in GPIIb by "loop-out" mutagenesis did not prevent heterodimer assembly; although like the heterodimer containing the Gly273 Asp mutation, the heterodimers were not transported to the cell surface (M. Kolodziej, M. Poncz, and J. S. Bennett, unpublished observations).
The inability of GPIIb-IIIa heterodimers containing the GPIIb mutant to be immunoprecipitated by either of two heterodimer-specific monoclonal antibodies suggests that the conformation of these heterodimers was altered by the point mutation in GPIIb. Although the epitopes recognized by these antibodies have not been identified, it is clear that the epitopes require the presence of an intact heterodimer ( 15 ) . Furthermore, ultrastructural studies indicate that one of the antibodies, A2A9, binds to the globular head ofGPIIb-IIIa composed of the amino-terminal portions of both GPIIb and GPIIIa (3). Thus, it is likely that the mutation altered the conformation of the amino terminus of GPIIb-IIIa sufficiently to impair its interaction with these antibodies.
The ER contains mechanisms that retain malfolded or improperly assembled proteins and protein complexes ( 31 ) . Because we found that recombinant heterodimers containing the GPIIb mutant did not contain cleaved GPIIb, a process that occurs in a Golgi or trans-Golgi compartment (12, 13) , it is likely that these heterodimers were retained by the ER. On the other hand, a small quantity ofGPIIb-IIIa appeared to be present on the surface of the patient's platelets, suggesting that the retention mechanism for this malfolded protein in the ER may (28, 33) , and two mutations produce a premature termination codon in the GPIIb reading frame (33, 34) . The sixth mutation, described in a preliminary report (35) , is Gly418 -* Asp substitution adjacent to the fourth calciumbinding domain ofGPIIb. This mutation, like the mutation we have described, appears to impair the intracellular trafficking ofGPIIb-IIIa. Seven different mutations have been detected in GPIIIa. One mutation results from the insertion of at least 7.2 kb into the GPIIIa gene (36), a second results from an 11-base deletion producing a frameshift and a premature termination codon (28) , and a third results from the loss of a splice donor site, aberrant mRNA splicing, and a shift in the reading frame, producing a premature termination codon (37) . The four remaining GPIIIa mutations consist of single amino acid substitutions and produce variant thrombasthenia in which normal or nearly normal numbers of nonfunctional GPIIb-IIIa heterodimers are expressed on the platelet surface. In one mutant, a Ser752 --Pro substitution in the cytoplasmic domain of GPIIIa prevents activation of the heterodimer (38) . The three other point mutations involve the extracellular domain of GPIIIa and are the result of the replacement of a charged amino acid with an uncharged residue (Asp 1 19 -. Tyr; Arg214 -> Trp/Gln) in regions of GPIIIa thought to be involved in ligand binding (39) (40) (41) . The reason point mutations in GPIIIa permit normal or nearly normal GPIIb-IIIa expression while the point mutation we detected in GPIIb does not is not obvious. It is possible, however, that the substitution of a charged by an uncharged amino acid has a less deleterious effect on the overall GPIIb-IIIa conformation than does the addition of additional charge to the region ofthe protein likely to have a well defined secondary structure.
